

UNITED STATES PATENT AND TRADEMARK OFFICE

---

BEFORE THE PATENT TRIAL AND APPEAL BOARD

---

MYLAN PHARMACEUTICALS INC.,  
Petitioner,

v.

POZEN INC. and HORIZON PHARMA USA, INC.,  
Patent Owners.

---

Case IPR2017-01995  
Patent 9,220,698

---

**PATENT OWNER'S EXHIBIT LIST**

### PATENT OWNER EXHIBIT LIST

EXHIBIT NO.	BRIEF DESCRIPTION
2001	Gabriel, S.E., et al., “Risk for Serious Gastrointestinal Complications Related to Use of Nonsteroidal Anti-inflammatory Drugs,” <i>Annals of Internal Medicine</i> , Vol. 115, No. 10, pp. 787-796 (1991) (“Gabriel”)
2002	Cryer, B. and Feldman, M., “Effects of Nonsteroidal Anti-inflammatory Drugs on Endogenous Gastrointestinal Prostaglandins and Therapeutic Strategies for Prevention and Treatment of Nonsteroidal Anti-inflammatory Drug-Induced Damage,” <i>Archives of Internal Medicine</i> , Vol. 152, pp. 1145-1155 (1992) (“Cryer”)
2003	Fries, J.F., et al., “Nonsteroidal Anti-Inflammatory Drug-Associated Gastropathy: Incidence and Risk Factor Models,” <i>The American Journal of Medicine</i> , Vol. 91, pp. 213-222 (1991) (“Fries”)
2004	Second Amended Complaint for Patent Infringement, <i>Horizon Pharma, Inc. v. Mylan Pharmaceuticals Inc.</i> , Civil Action No. 2:15-cv-03327 (D.N.J. Feb. 10, 2016)
2005	Answer to Second Amended Complaint, Separate Defenses, And Counterclaims by Defendants Mylan Pharmaceuticals Inc., Mylan Laboratories Limited and Mylan Inc. , <i>Horizon Pharma, Inc. v. Mylan Pharmaceuticals Inc.</i> , Civil Action No. 2:15-cv-03327 (D.N.J. Feb. 19, 2016)
2006	Plaintiffs’ Answer to Defendants’ Counterclaims to Second Amended Complaint, <i>Horizon Pharma, Inc. v. Mylan Pharmaceuticals Inc.</i> , Civil Action No. 2:15-cv-03327 (D.N.J. Mar. 7, 2016)
2007	157 Cong. Rec. S5429 (daily ed. Sept. 8, 2011) (statement of Sen. Kyl)

EXHIBIT NO.	BRIEF DESCRIPTION
2008	Declaration of Jonathan G. Graves in Support of <i>Pro Hac Vice Motion</i>
2009	Declaration of Susan Krumplitsch in Support of <i>Pro Hac Vice Motion</i>
2010	Email string from Mylan's counsel, Robert D. Swanson from February 6, 2017 to February 15, 2017

Date: March 22, 2018

Respectfully submitted,

BY: /Thomas A. Blinka/

Thomas A. Blinka, Ph.D.

Reg. No. 44,541

Counsel for Patent Owner

**CERTIFICATION OF SERVICE UNDER 37 C.F.R. § 42.6(e)**

I, Thomas A. Blinka, hereby certify that on this 22nd day of March 2018, the foregoing Patent Owner Exhibit List was served electronically via email on the following:

Brandon M. White  
[bmwhite@perkinscoie.com](mailto:bmwhite@perkinscoie.com)  
700 13<sup>th</sup> St., NW Suite 600  
Washington, DC 20005

Emily Greb  
[egreb@perkinscoie.com](mailto:egreb@perkinscoie.com)  
One East Main St., Suite 201  
Madison, WI 53703

[EsoNaproxen@perkinscoie.com](mailto:EsoNaproxen@perkinscoie.com)

Date: March 22, 2018

BY: /Thomas A. Blinka/  
Thomas A. Blinka, Ph.D.  
Reg. No. 44,541  
Counsel for Patent Owner